The pandemic has taken its toll, transforming many markets and sectors irrevocably. Organisations operating within the clinical trial space alongside cold chain collaborators have had to revaluate prepandemic processes. However, there are signs providing hope of lasting change within the industry, which will benefit patients and companies alike. Dave Williams at Peli BioThermal summarises the impact of the pandemic in the industry, one year after the start of the COVID-19 pandemic.